U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449702) titled 'An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis' on Feb. 26.
Brief Summary: An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
Plaque Psoriasis
Intervention:
DRUG: ORKA-001
ORKA-001 administered by subcutaneous (SC) injection
Recruitment Status: RECRUITING
Sponsor: Oruka Therapeutics, Inc.
Published by HT Digital Content Services with permission from Heal...